Last reviewed 2026-06-01 · How we verify

UNLOXCYT (COSIBELIMAB-IPDL)

CHECKPOINT THERAPEUTICS INC · FDA-approved approved Under review Quality 6/100

UNLOXCYT (generic name: COSIBELIMAB-IPDL) is a Programmed Death Ligand-1 Blocker [EPC] drug developed by CHECKPOINT THERAPEUTICS INC. It is currently FDA-approved.

Cosibelimab is an antibody that inhibits the programmed cell death 1 ligand 1, a protein involved in the immune system. It is being studied in clinical trials for the treatment of Cutaneous Squamous Cell Carcinoma, a type of skin cancer, particularly in patients with kidney transplant or hematologic malignancy.

At a glance

Generic name	COSIBELIMAB-IPDL
Sponsor	CHECKPOINT THERAPEUTICS INC
Drug class	Programmed Death Ligand-1 Blocker [EPC]
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Fatigue
Musculoskeletal pain
Rash
Diarrhea
Hypothyroidism
Nausea
Constipation
Headache
Pruritus
Edema
Localized infection
Urinary tract infection

Serious adverse events

Sepsis
Pneumonia
Pyrexia
COVID-19
Ulcerative keratitis
Tumor thrombosis
Cholestasis
Hepatic cytolysis
Pemphigoid
COVID-19 pneumonia

Key clinical trials

A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster) (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

UNLOXCYT CI brief — competitive landscape report
UNLOXCYT updates RSS · CI watch RSS
CHECKPOINT THERAPEUTICS INC portfolio CI

Frequently asked questions about UNLOXCYT

What is UNLOXCYT?

UNLOXCYT (COSIBELIMAB-IPDL) is a Programmed Death Ligand-1 Blocker [EPC] drug developed by CHECKPOINT THERAPEUTICS INC.

Who makes UNLOXCYT?

UNLOXCYT is developed and marketed by CHECKPOINT THERAPEUTICS INC (see full CHECKPOINT THERAPEUTICS INC pipeline at /company/checkpoint-therapeutics-inc).

What is the generic name of UNLOXCYT?

COSIBELIMAB-IPDL is the generic (nonproprietary) name of UNLOXCYT.

What drug class is UNLOXCYT in?

UNLOXCYT belongs to the Programmed Death Ligand-1 Blocker [EPC] class. See all Programmed Death Ligand-1 Blocker [EPC] drugs at /class/programmed-death-ligand-1-blocker-epc.

What development phase is UNLOXCYT in?

UNLOXCYT is FDA-approved (marketed).

What are the side effects of UNLOXCYT?

Common side effects of UNLOXCYT include Fatigue, Musculoskeletal pain, Rash, Diarrhea, Hypothyroidism, Nausea. Serious adverse events: Sepsis, Pneumonia, Pyrexia, COVID-19.

Drug class: All Programmed Death Ligand-1 Blocker [EPC] drugs
Manufacturer: CHECKPOINT THERAPEUTICS INC — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing